Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Nelson

Showing results (351-360 of 442) with videos related to

Pageof 45
Sort By:
Plos One|November 13, 2012
Hepatitis B virus infection in HIV-positive individuals in the UK collaborative HIV cohort (UK CHIC) studyHuw Price, Loveleen Bansi, Caroline A Sabin, et al.
Journal of Hepatology|September 22, 2016
HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western EuropePatrick Ingiliz, Thomas C Martin, Alison Rodger, et al.
The Journal of Infectious Diseases|August 6, 2013
Clinical factors that predict noncirrhotic portal hypertension in HIV-infected patients: a proposed diagnostic algorithmNeil D Parikh, Valerie Martel-Laferriere, Tatyana Kushner, et al.
BMC Geriatrics|December 19, 2021
Social isolation, social support and loneliness as predictors of cardiovascular disease incidence and mortalityRosanne Freak-Poli, Joanne Ryan, Johannes T Neumann, et al.
AIDS (London, England)|March 4, 2014
Laboratory adverse events and discontinuation of therapy according to CD4(+) cell count at the start of antiretroviral therapySophie Jose, Killian Quinn, Teresa Hill, et al.
Hepatology (Baltimore, Md.)|October 26, 2019
Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral InfectionMarianne Martinello, Chloe Orkin, Graham Cooke, et al.
Clinical Pharmacology and Therapeutics|June 21, 2020
Genetic Variation in PEAR1, Cardiovascular Outcomes and Effects of Aspirin in a Healthy Elderly PopulationJoshua P Lewis, Moeen Riaz, Sophia Xie, et al.
Hepatology (Baltimore, Md.)|May 27, 2006
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionRichard K Sterling, Eduardo Lissen, Nathan Clumeck, et al.
Leukemia & Lymphoma|December 5, 2012
A retrospective, multi-center analysis of treatment intensification for human immunodeficiency virus-positive patients with high-risk diffuse large B-cell lymphomaShireen Kassam, Mark Bower, Siow Ming Lee, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 25, 2016
Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? Epidemiological and Modeling InsightsNatasha K Martin, Alicia Thornton, Matthew Hickman, et al.
Pageof 45

Showing results (351-360 of 442) with videos related to

Sort By:
Pageof 45
Plos One|November 13, 2012
Hepatitis B virus infection in HIV-positive individuals in the UK collaborative HIV cohort (UK CHIC) studyHuw Price, Loveleen Bansi, Caroline A Sabin, et al.
Journal of Hepatology|September 22, 2016
HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western EuropePatrick Ingiliz, Thomas C Martin, Alison Rodger, et al.
The Journal of Infectious Diseases|August 6, 2013
Clinical factors that predict noncirrhotic portal hypertension in HIV-infected patients: a proposed diagnostic algorithmNeil D Parikh, Valerie Martel-Laferriere, Tatyana Kushner, et al.
BMC Geriatrics|December 19, 2021
Social isolation, social support and loneliness as predictors of cardiovascular disease incidence and mortalityRosanne Freak-Poli, Joanne Ryan, Johannes T Neumann, et al.
AIDS (London, England)|March 4, 2014
Laboratory adverse events and discontinuation of therapy according to CD4(+) cell count at the start of antiretroviral therapySophie Jose, Killian Quinn, Teresa Hill, et al.
Hepatology (Baltimore, Md.)|October 26, 2019
Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral InfectionMarianne Martinello, Chloe Orkin, Graham Cooke, et al.
Clinical Pharmacology and Therapeutics|June 21, 2020
Genetic Variation in PEAR1, Cardiovascular Outcomes and Effects of Aspirin in a Healthy Elderly PopulationJoshua P Lewis, Moeen Riaz, Sophia Xie, et al.
Hepatology (Baltimore, Md.)|May 27, 2006
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionRichard K Sterling, Eduardo Lissen, Nathan Clumeck, et al.
Leukemia & Lymphoma|December 5, 2012
A retrospective, multi-center analysis of treatment intensification for human immunodeficiency virus-positive patients with high-risk diffuse large B-cell lymphomaShireen Kassam, Mark Bower, Siow Ming Lee, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 25, 2016
Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? Epidemiological and Modeling InsightsNatasha K Martin, Alicia Thornton, Matthew Hickman, et al.
Pageof 45